CHEN ZHONGHUI – Trademark Portfolio
Entity Type: 01
CHEN ZHONGHUI owns a portfolio of 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as BAGAVS, BUYHANG, FANTMAT, HOMEMOH, and STAYEGN. Of these, 5 are registered. The portfolio spans 5 Nice Classification classes, led by Class 10 (Medical Apparatus) and Class 5 (Pharmaceuticals). Headquartered in Guangzhou, Guangdong.
G03, No. 12 Building
Guangzhou, Guangdong , CN
Showing of trademarks Trademarks
Trademark Classifications
CHEN ZHONGHUI's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Leather and imitations of leather; animal skins, hides; trunks and travelling bags
Games and playthings; gymnastic and sporting articles; decorations for Christmas trees
Frequently Asked Questions
How many trademarks does CHEN ZHONGHUI have?
CHEN ZHONGHUI has 7 U.S. trademarks filed with the USPTO. Of these, 5 registered.
What trademark classes does CHEN ZHONGHUI file in?
CHEN ZHONGHUI files trademarks across 5 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 18 (Leather Goods), Class 28 (Toys & Sporting Goods). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are CHEN ZHONGHUI's most well-known trademarks?
CHEN ZHONGHUI's registered trademark portfolio includes well-known marks such as BAGAVS, BUYHANG, FANTMAT, HOMEMOH, and STAYEGN. These are among 5 currently registered trademarks in the portfolio.
What is CHEN ZHONGHUI's trademark registration success rate?
CHEN ZHONGHUI has a 100% trademark registration rate, with 5 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.